Summary & Overview
HCPCS G0683: Application of Non‑Sheet Skin Substitute Graft, ≥100 sq cm
HCPCS Level II code G0683 designates the application of an FDA-regulated skin substitute graft (PMA, 510(k), or 361 HCT/P, non-sheet form) for large wound surfaces (≥100 sq cm or 1% body area in infants/children) and captures the first 100 sq cm of treated area. This code matters nationally because advanced biologic grafts are increasingly used for complex acute and chronic wounds, driving clinical choice, billing complexity, and payer policy development. Payers frequently address coverage criteria, documentation expectations, and site-of-service considerations for these expensive, high-acuity treatments.
Key payers covered in this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of what G0683 represents, clinical contexts where it applies, and the typical settings where the service is delivered. The publication outlines common policy themes and coverage triggers used by major payers, summarizes available national benchmarks when present, and highlights coding relationships important for claims submission. Data limitations are noted when specific payer policy details are not available in the input. The goal is to give clinicians, billing professionals, and policy analysts a clear, actionable reference on the clinical meaning, typical sites of service, and payer landscape tied to HCPCS Level II code G0683.
Billing Code Overview
HCPCS Level II code G0683 describes the application of a premarket approval (PMA), 510(k), 361 human cells, tissues or cellular and tissue-based product (HCT/P) non-sheet form skin substitute graft for a wound surface greater than or equal to 100 square centimeters; first 100 sq cm wound surface area, or 1% of body area of infants and children.
Service type: Skin substitute graft application for large wound surfaces.
Typical site of service: Hospital outpatient departments, wound care centers, specialty clinics, and other ambulatory surgical settings where biologic grafts are applied to acute or chronic wounds requiring substantial surface coverage.
Clinical & Coding Specifications
Clinical Context
A 62-year-old male with a chronic full-thickness lower extremity wound from prior traumatic degloving and delayed healing presents to a hospital-based outpatient wound clinic. The wound measures 140 square centimeters with exposed subcutaneous tissue and stalled granulation despite optimized local care (debridement, topical therapy, offloading, infection control). After multidisciplinary evaluation, the clinician documents suitability for a cellular/tissue-based product non-sheet skin substitute that is approved via PMA/510(k)/361 pathway. The procedure is scheduled in the ambulatory procedure suite. The workflow includes pre-procedure wound assessment and photography, sharp surgical or enzymatic debridement under local anesthesia, irrigation and hemostasis, size measurement and area calculation, and application of the graft product to the first 100 sq cm of wound surface area billed under G0683. The clinician instructs standard post-application dressing and schedules follow-up visits at 1 week and 2–4 weeks to assess graft take, manage dressings, and document progress. If additional wound area beyond the initial 100 sq cm is treated with the same product, an additional unit or subsequent HCPCS should be considered per payor guidance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service | Use when a separate and distinct procedure unrelated to is performed on the same date (e.g., a separate surgical closure on a different wound). |